Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Following the publication of this article the authors noted that the MRD data under the Table 1 column "Remark" of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

Correction to: Leukemia 32, 252–262 (2018);

10.1038/leu.2017.329;

published online February 2018

Following the publication of this article the authors noted that the MRD data under the Table 1 column “Remark” of Aspire should go to that of Pollux. The authors wish to apologize for any inconvenience caused. The corrected table is attached to this correction.

Table. Major clinical trials of next generation PIs (carfilzomib, Ixazomib), next generation IMiDs (pomalidomide) and monoclonal antibody.